Bell & Brown Wealth Advisors LLC acquired a new position in Gilead Sciences (NASDAQ:GILD) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 18,710 shares of the biopharmaceutical company’s stock, valued at approximately $1,340,000.
Several other institutional investors have also recently added to or reduced their stakes in GILD. Yorktown Management & Research Co Inc acquired a new stake in Gilead Sciences during the 4th quarter valued at approximately $1,504,000. Investors Research Corp acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $340,000. First Interstate Bank grew its position in shares of Gilead Sciences by 2.0% in the 4th quarter. First Interstate Bank now owns 119,468 shares of the biopharmaceutical company’s stock worth $8,559,000 after acquiring an additional 2,367 shares in the last quarter. Aevitas Wealth Management Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $377,000. Finally, Amalgamated Bank grew its position in shares of Gilead Sciences by 9.6% in the 4th quarter. Amalgamated Bank now owns 169,797 shares of the biopharmaceutical company’s stock worth $12,164,000 after acquiring an additional 14,926 shares in the last quarter. Institutional investors own 78.35% of the company’s stock.
In other Gilead Sciences news, Director Gayle E. Wilson sold 60,000 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $77.92, for a total value of $4,675,200.00. Following the completion of the sale, the director now owns 182,258 shares of the company’s stock, valued at $14,201,543.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $83.56, for a total value of $4,178,000.00. Following the transaction, the chairman now directly owns 3,046,766 shares of the company’s stock, valued at approximately $254,587,766.96. The disclosure for this sale can be found here. Insiders sold 308,600 shares of company stock valued at $24,328,226 in the last ninety days. Insiders own 1.16% of the company’s stock.
Shares of NASDAQ GILD opened at $74.69 on Tuesday. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53. Gilead Sciences has a one year low of $63.76 and a one year high of $89.54. The stock has a market capitalization of $98,075.59, a price-to-earnings ratio of 8.73, a PEG ratio of -1.73 and a beta of 1.18.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter in the previous year, the firm earned $2.70 earnings per share. The business’s quarterly revenue was down 18.7% compared to the same quarter last year. equities research analysts anticipate that Gilead Sciences will post 6.21 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Shareholders of record on Friday, March 16th were given a $0.57 dividend. The ex-dividend date of this dividend was Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.05%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is currently 26.64%.
A number of research analysts recently issued reports on the company. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, April 11th. Barclays restated an “overweight” rating and set a $95.00 price objective (up previously from $90.00) on shares of Gilead Sciences in a research report on Tuesday, March 6th. BidaskClub downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Royal Bank of Canada reaffirmed a “buy” rating and set a $94.00 target price on shares of Gilead Sciences in a research note on Friday, February 23rd. Finally, Leerink Swann reaffirmed a “market perform” rating and set a $80.00 target price (down previously from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $88.61.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.